Skip to main content

Table 2 Characteristics of the random sample of EPIC-NL (n=1886)

From: Single nucleotide polymorphisms (SNPs) involved in insulin resistance, weight regulation, lipid metabolism and inflammation in relation to metabolic syndrome: an epidemiological study

  Total (n=1886) Men (n=465) Women (n=1421)
Sex (% men) 24.6 (465)   
Age (yr) 50.1 (11.7) 43.9 (11.1) 52.2 (11.2)
Waist circumference (cm) 85.5 (11.6) 92.0 (11.4) 82.9 (10.5)
Abdominal obesity(%)a 27.7(522) 21.9 (102) 29.6 (420)
HbA1C (%) 5.46 (0.69) 5.27 (0.61) 5.53 (0.71)
Hyperglycemiaa 28.3 (534) 17.8 (83) 31.7 (451)
Diabetic medication(%) 1.2 (22) 0.2 (1) 1.5 (21)
HDL-cholesterol (mmol/L) 1.27 (0.35) 1.14 (0.28) 1.31 (0.36)
Low HDL-cholesterol(%)a 47.8 (902) 29.2 (136) 53.9 (766)
Triglyceride (mmol/L) b, c 1.32 (0.91-1.98) 1.72 (1.15-2.40) 1.22 (0.85-1.80)
Hypertriglyceridemia a, b 33.8 (637) 50.8 (236) 28.2 (401)
Systolic blood pressure (mm Hg) 126.9 (18.5) 127.1 (14.8) 126.8 (19.5)
Diastolic blood pressure (mm Hg) 78.2 (10.4) 80.3 (10.1) 77.5 (10.4)
Hypertension(%)a 45.6 (860) 47.1(219) 45.1 (641)
Blood pressure lowering medication (%) 10.7 (202) 5.6 (26) 12.4 (176)
High sensitive CRP (mmol/L) 1.41 (0.62-3.39) 1.20 (0.53-2.82) 1.49 (0.66-3.70)
MetS-score (number of features) 1.8 (1.4) 1.7 (1.3) 1.9 (1.4)
MetS prevalence(%)a 30.3 (572) 25.2 (117) 32.0 (455)
  1. Data are presented as means (standard deviation), median with inter-quartile range or % (n); HbA1C haemoglobin A1c, MetS metabolic syndrome, hsCRP high sensitive C-reactive protein.
  2. aAbdominal obesity, low HDL cholesterol, hypertension, hypertriglyceridemia and MetS are defined according to the criteria of AHA-NHLBI (2005). Hyperglycemia is defined according to the criteria of the American Diabetes Association (2010). Abdominal obesity: ♂ ≥102 cm; ♀≥ 88 cm; Low HDL: ♂ <1.0; ♀<1.3 mmol/L; Hypertriglyceridemia: ≥1.7 mmol/L; Hypertension: ≥130/85 mm Hg or use of hypertensive medication; Hyperglycemia: HbA1C in National Glycohemoglobin Standarization Program (NGSP) units ≥ 5.7% or glucose lowering medication; MetS is defined as having at least 3 MetS features.
  3. bNon-fasting values.
  4. cNo information on lipid lowering medication is available.